III

Worried_Quarter469

Iran War III was the bottom

Affectionate-Idea690

U have to be batshit crazy to think a country can impose tolls...it's non existent  UNCLOS Part III (Articles 37–44), all ships and aircraft enjoy the right of continuous and expeditious "transit passage" through straits used for international navigation. Coastal states bordering these straits are legally prohibited from hampering, suspending, or blocking this passage. Just nuts that wall street is that dumb. SMH 

Weekly-Barracuda-494

I think it has been a little disappointing. Look, I am just an investor with a science degree, I don't claim to know what will happen with this stock, but the market cap last Thursday was 127MM, based on $2.20 share price. It is crazy, but based on initial milestone payments due for sales volumes, It looks like it is undervalued by a factor of 2 1/2 - three times that in sales level bonuses and milestone payments. I am not sure about returns and don't want to do the math to find net present value of future streams, but GSK has around 16% of the company's shares, this from a basic Google search on the initial agreement: The exclusive license agreement between Spero Therapeutics (**SPRO**) and **GSK** for the oral antibiotic tebipenem HBr (commercialized as **Utebzi**) is structured to transition global commercialization rights to GSK while providing Spero with substantial upfront capital, developmental milestones, and ongoing sales revenue. \[[1](https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis/), [2](https://www.globenewswire.com/news-release/2022/09/22/2520704/0/en/gsk-and-spero-therapeutics-announce-exclusive-license-agreement-for-late-stage-antibiotic-asset-tebipenem-hbr.html)\] 1. Upfront Payments & Equity (2022) When the agreement was finalized and closed in late 2022, GSK provided Spero with immediate capital to fund the phase III clinical trial: \[[1](https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/d370224d8k.htm), [2](https://www.biospace.com/spero-therapeutics-announces-closing-of-exclusive-license-agreement-with-gsk-for-tebipenem-hbr), [3](https://www.biospace.com/gsk-and-spero-therapeutics-announce-exclusive-license-agreement-for-late-stage-antibiotic-asset-tebipenem-hbr), [4](https://firstwordpharma.com/story/5672810)\] * **Upfront License Fee:** **$66 million** cash paid to Spero for exclusive rights. * **Equity Investment:** **$9 million** direct investment. GSK purchased 7,450,000 shares of Spero common stock at approximately $1.21 per share. \[[1](https://us.gsk.com/en-us/media/press-releases/gsk-and-spero-therapeutics-announce-exclusive-licence-agreement-for-tebipenem-hbr-a-late-stage-antibiotic-that-may-treat-complicated-urinary-tract-infections/), [2](https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/d370224d8k.htm), [3](https://www.biospace.com/spero-therapeutics-announces-closing-of-exclusive-license-agreement-with-gsk-for-tebipenem-hbr)\] 1. Milestone Payment Structure The deal outlines up to **$525 million** in total potential milestone payments across three distinct phases of the drug's lifecycle: \[[1](https://www.biospace.com/spero-therapeutics-announces-closing-of-exclusive-license-agreement-with-gsk-for-tebipenem-hbr), [2](https://firstwordpharma.com/story/5765775)\] |**Phase \[**[1](https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/d370224d8k.htm)**,** [2](https://firstwordpharma.com/story/5765775)**,** [3](https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/d107475dex991.htm)**,** [4](https://finance.yahoo.com/news/spero-announces-nda-resubmission-tebipenem-130000983.html)**,** [5](https://pharmaphorum.com/news/gsk-will-file-oral-carbapenem-complicated-utis-year)**\]**|**Milestone Description**|**Maximum Payout**| |:-|:-|:-| || |**Development & Regulatory**|Paid out as the Phase 3 trial progressed and regulatory filings were made. Includes a **$25 million** payment triggered by the FDA NDA resubmission.|**$150 million total**| |**First Commercial Sales**|Triggered upon the first commercial sales of the drug in the United States and Europe.|**$150 million total**| |**Annual Sales Milestones**|Tiered cash payments triggered as cumulative global net sales cross specific revenue hurdles.|**$225 million total**| Breakdown of the $225M Sales Milestones: * **$25 million** when net annual sales exceed $200 million * **$25 million** when net annual sales exceed $300 million * **$25 million** when net annual sales exceed $400 million * **$50 million** when net annual sales exceed $500 million * **$50 million** when net annual sales exceed $750 million * **$50 million** when net annual sales exceed $1 billion \[[1](https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/d370224d8k.htm)\] 1. Tiered Royalty Percentages Spero is entitled to continuous, tiered royalties on net product sales within GSK’s territories: \[[1](https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/d370224d8k.htm), [2](https://firstwordpharma.com/story/5765775)\] * **Rate Scale:** Ranges from **low-single digits to low-double digits** (the highest tier is unlocked if annual net sales exceed $1 billion). * **Adjustments:** Royalties are subject to standard reduction clauses if third-party licenses are required, if a generic version enters the market, or if patent exclusivity expires before the 10th anniversary of the first commercial sale. \[[1](https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/d370224d8k.htm)\] 1. Operational Division of Labor * **Spero's Role:** Responsible for the operational execution and initial costs of the follow-up Phase 3 trial (the PIVOT-PO study, which successfully finished early for efficacy). \[[1](https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/d370224d8k.htm), [2](https://finance.yahoo.com/news/spero-announces-nda-resubmission-tebipenem-130000983.html)\] * **GSK's Role:** Holds exclusive rights to develop and commercialize the drug globally. GSK assumed full responsibility for additional clinical development, regulatory submissions, and all commercial launch and marketing costs. \[[1](https://www.gsk.com/en-gb/media/press-releases/gsk-and-spero-therapeutics-announce-exclusive-licence-agreement-for-tebipenem-hbr-a-late-stage-antibiotic-that-may-treat-complicated-urinary-tract-infections/)\] * **Excluded Territories:** The agreement covers all global territories *except* Japan and select Asian countries, which are retained by Spero’s long-standing partner, Meiji Seika. \[[1](https://www.gsk.com/en-gb/media/press-releases/gsk-and-spero-therapeutics-announce-exclusive-licence-agreement-for-tebipenem-hbr-a-late-stage-antibiotic-that-may-treat-complicated-urinary-tract-infections/), [2](https://finance.yahoo.com/news/spero-announces-nda-resubmission-tebipenem-130000983.html)\] Not sure, but think Spero has already gotten first $150 million, so $325 million? in milestones remain in addition to royalties paid out on sales, looked like flat rate of 1% to first $750 million then ascending from $750 million to a max low double digit royalty on sales of over $1 billion. I got this off of Stock Titan article, showing parts of 10K Spero's annual report? |**Contingent Event**|**Milestone Payment**| | |:-|:-|:-| || |**Total potential commercial milestones based on first commercial sales**|**$101.0**\*| | |First commercial sale of a product in the United States| \-|$51.0| |Second anniversary of first commercial sale of a product in the United States| \-|$25.0| |First commercial sale of a product in two European countries| \-|$25.0| |**Total potential sales milestone payments**|**$225.0**| | |Net annual sales greater than $200.0| \-|$25.0| |Net annual sales greater than $300.0| \-|$25.0| |Net annual sales greater than $400.0| \-|$25.0| |Net annual sales greater than $500.0| \-|$50.0| |Net annual sales greater than $750.0| \-|$50.0| |Net annual sales greater than $1,000.0| \-|$50.0|   \*Under the terms of the GSK License Agreement, the maximum potential milestone amount was revised from $150.0 million after PIVOT-PO was stopped early for efficacy following completion of a pre-specified interim analysis of data from 1,690 patients enrolled in the trial, thereby reducing the overall cost of the trial to the Company; the maximum potential milestone payment of $150.0 million was contingent upon the trial continuing to full enrollment, with 2,637 patients enrolled in the trial. In addition to the milestones described above, GSK is obligated to pay us royalties on annual net sales of GSK Licensed Products in the GSK Territory. Such royalties are 1% for annual sales up to $750.0 million each year and range from high single-digit percentages on annual net sales above $750.0 million each year to low double-digit percentages on annual net sales above $1,000.0 million each year. Even though Spero is a one trick pony, after discontinuing the rest of their pipeline, I would think a buyout would benefit both parties. GSK may be waiting to see how drug sales are going upon the introduction in late 2026 that they project, but a successful launch would only increse the buyout price. I am not making a recommendation, and I have no expertise in this area. Do your own due diligence if you plan on pursuing this stock.

fenton7

It was wildly overvalued. Yes there's some geopolitical risk but Gold has been priced for World War III.

bananastock

I wanted to know how long after the hearings it will take to get final rule.........The below is AI While the Drug Enforcement Administration (DEA) hearings are scheduled to conclude no later than **July 15, 2026**, an immediate final ruling on adult-use/recreational cannabis will not happen overnight. Federal rulemaking requires a multi-step administrative process once the hearings wrap up. Here is the timeline of what has to happen next: # The Post-Hearing Process 1. **ALJ Recommendation (Weeks to Months):** After the hearing closes, Chief Administrative Law Judge (ALJ) Derek C. Julius must review the presented evidence, expert testimony, and hearing transcripts. He will then draft findings and a "recommended decision." There is no strict statutory countdown for this step—standard ALJ decisions often take 30 to 90 days, though complex federal dockets can take longer. 2. **DEA Administrator Review:** The ALJ’s recommendation is sent to the DEA Administrator, who reviews the findings to make a final determination. 3. **Final Rule Publication:** If the DEA decides to reschedule marijuana as a whole, they will draft and publish a Final Rule in the Federal Register. # The "Expedited" Factor This process is operating under an accelerated timeline. In December 2025, an Executive Order was issued directing the Attorney General to complete the rescheduling process "in the most expeditious manner in accordance with Federal law." Because of this mandate, the post-hearing review process will likely be compressed compared to traditional bureaucratic timelines. # Pending Legal Hurdles Even when the DEA issues a Final Rule for adult-use/recreational cannabis, it will not be the end of the road. When the Department of Justice issued its final order in April 2026 that immediately moved FDA-approved and state-licensed **medical** marijuana to Schedule III, multiple organizations and state attorneys general filed lawsuits in the D.C. Circuit Court of Appeals to block it. You should expect any final rule expanding Schedule III to adult-use cannabis to face immediate and aggressive legal challenges, which could delay the actual implementation.

sumguysr

Why would you make it schedule III unless you're planning to crack down on recreational use after the midterms?

Rich_Housing971

with a speedy Pentium III processor.

movdqa

The math theory stack behind modern AI is tall. Calculus I, II, III, Linear Algebra, Differential Equations, Statistics, Numerical Methods and Optimization. And Artificial Intelligence of course. It would probably help to have the discrete mathematics from traditional computer science. It's hard to learn all of this in an undergraduate degree without a head start in high-school which implies acceleration in elementary and middle-school. NAEP math and reading proficiency in the United States are about 22% and 35% respectively at the twelfth-grade level. Look up the PISA and TIMSS rankings of China and the United States. They are also starting with a much larger number of kids too. This is why Google has hired a lot of AI researchers from China.

SPAC_Time

[HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Pursue Nasdaq Listing](https://www.globenewswire.com/news-release/2026/07/09/3325251/0/en/hcc-healthcare-signs-business-combination-agreement-with-rf-acquisition-corp-iii-to-pursue-nasdaq-listing.html) \- RFAM RFAMR

Slight_Bet660

A better play in the sector is LIEN (Chicago Atlantic BDC). That is the company that loans to marijuana companies. Given all of the regulatory risk they have been able to be very selective in which companies they loan to and have been able to secure extremely lender-friendly terms. If rec weed gets rescheduled to schedule III and 280E gets killed, then the credit profiles of the companies that LIEN lends to improves overnight, the value of their existing book of loans shoots up, the stock price shoots up, and they probably get bought out by one of the large financial institutions who were previously prohibited from operating in the space.

DaveHervey

Nice to hear a crop was harvested. thanks for the news read this article and you might believe its a bigger market: Opinion: The Coming Divide Between Pharma THC and Retail Cannabis https://www.reddit.com/r/TLRY/comments/1us20dh/opinion_the_coming_divide_between_pharma_thc_and/ "2. Cannabis crosses the U.S. border legally for the first time April’s rescheduling order did something no cannabis policy before ever did: It placed marijuana drug products and state-licensed medical marijuana on the Schedule III import and export list. A single cannabis-derived drug had crossed under research permits before. This is a standing commercial pathway, and that is new. Every country that spent the past decade building medical cannabis for export — Israel, Colombia, Canada, the Netherlands — now has a legal door into the largest market on earth. The first permits will move FDA-approved products and Active Pharmaceutical Ingredients. State-licensed material is likely to follow as the frameworks catch up. But the wall around American cannabis was the last one standing, and it just grew a gate. Once foreign material lands cheaper than domestic material, the pressure runs in only one direction".

purplecatfishbettie

ambitious: "Hyperscale Data, Inc. owns and manages a data center and provides mission-critical products for the defense and aerospace, industrial, automotive, telecommunications, medical and biopharma, and textile industries. It operates through the following segments: Sentinum, Energy and Infrastructure, AGREE, Gresham, TurnOnGreen, Technology and Finance, and ROI. The Sentinum segment involves crypto asset mining operations, colocation and hosting services for emerging AI ecosystems and other industries, and digital asset treasury activities. The Energy and Infrastructure segment involves crane rental and lifting solutions provider for oilfield, construction, commercial and infrastructure markets. The AGREE segment involves hotel operations and other commercial real estate holdings. The Gresham segment involves defense solutions with operations conducted by Enertec, Relec, Microphase and Giga-tronics. The TurnOnGreen segment involves commercial electronics solutions with operations conducted by Digital Power, and electric vehicle (“EV”) charging solutions through TOG Technologies. The Technology and Finance segment involves commercial lending and trading through Ault Lending. The ROI segment involves askROI, which operates OnlyBulls, a consumer-facing financial research and market intelligence platform developed and operated by askROI as well as ROI’s own operations. The company was founded by Milton C. Ault III in 1969 and is headquartered in Las Vegas, NV." despite all the past dilution, it might be worth buying a bit...

AverageNo130

>SAM Witness Acknowledges Marijuana Fits Schedule III Definition During DEA Rescheduling Hearing MH

KAI5ER

Fun little tidbit of news unintentionally from from SAM. **The Schedule III "Gotcha" Moment**: During a remarkably brief, **five-minute cross-examination** by the DEA, Dr. Madros (SAM's star witness) was asked whether cannabis fits the legal definition of **Schedule III**, and she answered ***yes.***

SPAC_Time

[Spring Valley Acquisition Corp. III Shareholders Approve Business Combination with General Fusion](https://www.globenewswire.com/news-release/2026/07/06/3322805/0/en/Spring-Valley-Acquisition-Corp-III-Shareholders-Approve-Business-Combination-with-General-Fusion.html) \- SVAC SVACW "The closing of the transaction is expected to occur on or about Friday, July 10, 2026, subject to regulatory approvals and the satisfaction or waiver of all closing conditions. At the closing, Spring Valley will be renamed “General Fusion Group Ltd.” Shortly thereafter, the combined company’s shares and warrants are expected to trade on the Nasdaq under the ticker symbols “GFUZ” and “GFUZW,” respectively, subject to approval of its listing application." No redemption info yet.

Romanizer

It just shows how fundamentally wrong Bitcoin is both priced and seen from a risk perspective. Buying a stock of a company holding Bitcoin is easier and has a lower risk premium/weighting than buying the Bitcoin directly, which doesn't make sense at all. The perception that Bitcoin is a risk-asset needs to fall, which is currently being worked on by revaluation of Basel III guidelines.

FeverTreeCloud

Bring back Pentium III 😤

KAI5ER

Using the last of my Fable5 access ;) **The government came out swinging and rested fast.** The DEA's lead counsel opened by framing the entire hearing around "currently accepted medical use" (CAMU) — arguing that if even one accepted medical use exists, marijuana legally cannot stay in Schedule I. The government presented just two witnesses: Dr. Dominic Chiapperino of the FDA, who described the scientific process behind the Schedule III recommendation, and Dr. Corey Burchman, a pain physician who testified about transitioning patients from opioids to marijuana. The government rested its case-in-chief within four days. **Crucially, the legal framing favors rescheduling:** HHS's scientific and medical determinations on CAMU bind the DEA by statute, and Julius said he can't entertain arguments about whether the HHS two-part test is legally permissible. That dramatically limits what the opposition can attack. **The opposition has shifted strategy.** NDASA's witnesses focused on workplace drug testing and transportation safety rather than challenging the medical science — and legal observers note their arguments may do opponents more good in judicial review or public messaging than before the ALJ on the merits. Translation: they're building a record for the D.C. Circuit appeal, not trying to win the hearing. **SAM's Kevin Sabet is publicly rattled** — calling the government's testimony "surreal" and claiming they're "lying through their teeth". That's not what winning sounds like. **What's left:** SAM, DUID Victim Voices, Finn, Tennessee Bureau of Investigation, Drum, and the four states present after the recess — so this week through July 15. Updated odds: I'd nudge **Schedule III finalization up to \~85%**. The hearing is going about as well as the pro-rescheduling side could hope. The post-order Barr lawsuit remains the real fight.

Valkyrie_Skuld

Someone should name something that should have an awesome name arthritis III

Total_Schedule591

Arthritis III is going to Uranus 🦸‍♂️

OX45-Tall

Tilray Brands, Inc. (TLRY) first gained widespread recognition as a "meme stock" during the massive 2021 retail trading frenzy, heavily driven by viral social media attention and speculation around U.S. cannabis legalization **The Meme Factor** **Retail Sentiment:** The stock frequently trends across communities like Reddit’s penny stock and trading forums. The narrative typically revolves around U.S. federal cannabis reclassification (e.g., Schedule III shifts), potential short squeezes, and the stock's highly beaten-down valuation. Even AI calls it a meme stock…..

REEMFMetalHead

I'm sure if we weren't in the middle of a run-up into World War III, investing in movies and television would be a fantastic idea.

-aibohphobia-

You poor boy. He’s not talking about the World Cup. He’s talking about World War III.

ebfeebfe

*CENTCOM says US forces bombed Iranian missile/drone storage locations and coastal radar sites tonight. CENTCOM added that the strikes tonight were in response to Iran's attack yesterday that "clearly violated the ceasefire."* Ceasefire III - A good day to cease hard Ceasefire IV - Kill them all Ceasefire V - Cease5ire

Relevant-Goal-3008

CXApp Inc. reported the results of its annual stockholder meeting. A quorum of 30,592,312 shares, or 44.32% of common stock entitled to vote as of April 17, 2026, was present or represented by proxy. Stockholders elected Khurram P. Sheikh and Vishal Mathai as Class III directors, each to serve until the annual meeting following the fiscal year ending December 31, 2028. They also approved the issuance of shares of common stock, or securities convertible into or exercisable for common stock, in one or more private placements in excess of 20% of outstanding common stock. Stockholders authorized the Board to implement, at its discretion, a reverse stock split with a ratio between 1-for-5 and 1-for-100 to help maintain CXApp’s Nasdaq listing and to amend the certificate of incorporation accordingly. They further approved, on a non-binding basis, executive compensation and set annual advisory votes on pay, and ratified WithumSmith+Brown, PC as independent registered public accounting firm for the year ending December 31, 2026.

aliph

First, their markets are massive. Second, they provide high value widgets, and they don't really have competitors so they can set their own prices. Therefore the value of their potential future success is tremendous. If you multiply probability of success times value of success you get an expected value. Their quality of execution is tremendous so the market gives them forward credit for achieving things beyond what they have achieved today, and a higher probability of success. Therefore, they will trade based on a pulled forward valuation of what the market expects them to do. Right now the market is basically priced for them building Colossus II and III and achieving a fully reusable Starship even though they technically haven't done those things.

redditmodsRrussians

Short Circuit III: One Won To Lose

DipSniper69

Mangowars Episode III Revenge of the bears

RealCanadianMonkey

Only companies with a predominantly medical cannabis business can realistically benefit from a Schedule III restructuring. If most of a company's revenue comes from recreational cannabis, moving away from that segment would significantly hurt its financial results, while Schedule III would provide little benefit to that recreational business. Trulieve was able to restructure because approximately 85% of its business is already medical cannabis.

FrequentUpperDecker

Warsh’s master plan: I) Deregulate. Trim SLR requirements as it relates to treasuries II) Decrease fed’s balance sheet. Trim some treasuries. III) Cut rates Back door money printer. Banks become much more involved in the bond market. Money gets cheaper. Fed is innocent because they are decreasing their balance sheet!

likamuka

SPACEX YNVESTORS BET ON RUG-PULL GALORE SpaceX investors appear focused on long-term gains rather than quick profits, according to Interactive Investor’s Richard Gaylord Hunter III. Bat-shit retail demand after the IPO suggests the stock is becoming a bag holder portfolio holding with a spastic target valuation of 5 trillion munchies. Shares climbed nearly 10% premarket to $211.64, trading 4556% above the actual true value of $1.35 price after a strong post-listing rally.

Spirit_of_Hogwash

Hey, their space division is going so well that even Bezos's lunar lander is.. ahead of theirs. The plan for Artemis III announced last week is having the astronauts dock with and fully test Bezos moon lander, but just dock with SpaceX's because it will not have any operational life support system. At this rate, I guess the Chinese will get to the moon before them.

SPAC_Time

[General Fusion’s Joint F-4 with Spring Valley Acquisition Corp. III in Connection with Proposed Business Combination Declared Effective by SEC; SVAC Schedules July 6, 2026 Shareholder Meeting to Vote For Business Combination with General Fusion](https://www.globenewswire.com/news-release/2026/06/15/3311736/0/en/general-fusion-s-joint-f-4-with-spring-valley-acquisition-corp-iii-in-connection-with-proposed-business-combination-declared-effective-by-sec.html) \- SVAC SVACW

BinaryGrind

The OG Xbox processor was a bog standard Intel Pentium III Celeron 733. There where export controls in place for the CPU but not because it was in the Xbox specifically, and only to really specific countries at the time.

ThePinkySuavo

It's just day one, we have have SpaceX on stock now, 2027/2028 Artemis III and Artemis IV launch, I think at least LUNR should benefit from it. I believe space stocks will be hyped. I might be wrong but I believe it, it just needs time. AI stocks also didn't grow up immediately

Total_Schedule591

Arthritis III crew selected

Thetamancer

Very thoughtful post. A minor clarification that the act of filing isn't what will allow Elite to sell upon the patent expiration date in August 2027. Rather, it's that Paragraph III is a different approval process from Paragraph IV. Briefly, under Paragraph IV, the generic manufacturer asserts that the patent is invalid and requests approval to manufacturer prior to the patent expiration date. Under Paragraph III, the applicant concedes the patent is valid and is requesting approval to manufacture after the expiration date. Paragraph IV filers are "rewarded" with the 180-day exclusivity window. Paragraph III filers don't have the same exclusivity window. Importantly, Paragraph IV exclusivity only blocks the FDA from approving another manufacturer under Paragraph IV. Paragraph III approval is still on the table even during a Paragraph IV exclusivity window. To pull it all together, Elite gets to produce in August 2027 under Paragraph III (assuming pre-approval by the FDA), but other manufacturers will be able to apply under Paragraph III as well to produce in August 2027. This is my understanding, but I certainly welcome further clarification if I've missed anything.

Bravadette

Why wouldnt it just be like Armitage III

kokatsu_na

Hmm, HLXC (Helix Acquisition III) probably? It's one of the best SPAC sponsors in the healthcare niche.

Paul_Robert_

“No.” \-William Shakespeare, Hamlet, Act III, Scene III, Line 87

GloomyMembership4197

Artemis III crew announced: MOON it is then.

tika_dengu

Nasa announces Artemis III and fake space stocks are meh

Jax_Alltrade

NLCP and Trulieve are my favorites in the sector. I also own CRLBF and IIPR. Those I consider riskier, with CRLBF being the riskiest. I purchased almost all of my IIPR when it was yielding 14-16%, so if it cuts to 10% and dump 20-40% of value I'm sitting on a harvestable capital loss while still making 10% on my initial investment which is an extraordinarily good dividend. I'm not sure they will have to cut either; the entire sector is about to fly up when the 280E write-offs start being reflected in the earnings reports. Give it a year, maybe less. Their renegotiations of leases were very involved and I believe (I could be mistaken here) that some of those include repayments of previous defaults if profits increase sufficiently. Even if this is a return to previous rent levels their AFFO will drop below 100 which will immediately remove the need to cut. Sentiment is also still in the toilet. Look at the the threads here and on X; plenty of people got burned when the pandemic run-up hype cycle took a shit. I got burned too; I had like $25,000 of Trulieve with a purchase price of $50. Ended up capitulating in the 30s. Repurchased a bigger position in the $5 range. We've had several cycles of hype related to rescheduling/legalization. People are sick and tired of hearing it. This time, however, has two notable differences: 1.) Cannabis was actually rescheduled to III allowing for 280E write-offs 2.) The 2018 farm bill hemp loophole was closed. While I are morally and ethically opposed to this it will benefit the MMJ/Rec sector in two ways, potentially: a.) It will trigger a hype cycle for full legalization as a $28 billion industry faces catastrophe in November or b.) It will shunt an appreciable fraction of that $28 billion industry to Medical/Rec. The latter would see a noticeable, nationwide uptick in sales which would be reflected in earnings Q1 and Q2 of next year. My personal belief is that the write-offs alone will make a lot of companies highly profitable. That, combined with the continued growth of cannabis as it displaces alcohol among Gen Z (and maybe Gen A, eventually) leads to a sector-wide bull case. TLDR: Everyone is pissed they got burned 5 years ago, nobody has any faith in the sector, sentiment is shit, but my fundamental analysis indicates a massive surge coming in the relatively near future. The time to buy was 6 months ago, but now is still good. Also, REITs like NLCP are great. If NLCP keeps this exact structure for the next 10 years I'll reinvest my dividends every quarter. 11%+ is an excellent return, even if I have to pay income taxes on it. IIPR would be the same if they weren't overextended, but I expect that overextension to resolve within 12 months, with a reasonable chance they continue to cover.

Sweaty_Platypus69

Weird.. NASA is having an update on the Artemis III.. and space / AI stocks are drilling.. lulz..

jerome-yellen

Patriarch Theophilos III will save the markets

DoinIt4DaShorteez

bro it's whatever Congress and the CTFC decides it is. 7 U.S. Code § 7a-2 - Common provisions applicable to registered entities (C) Special rule for review and approval of event contracts and swaps contracts (i) Event contracts In connection with the listing of agreements, contracts, transactions, or swaps in excluded commodities that are based upon the occurrence, extent of an occurrence, or contingency (other than a change in the price, rate, value, or levels of a commodity described in section 1a(2)(i) [2] of this title), by a designated contract market or swap execution facility, the Commission may determine that such agreements, contracts, or transactions are contrary to the public interest if the agreements, contracts, or transactions involve— (I) activity that is unlawful under any Federal or State law; (II) terrorism; (III) assassination; (IV) war; (V) gaming; or (VI) other similar activity determined by the Commission, by rule or regulation, to be contrary to the public interest . (ii) Prohibition No agreement, contract, or transaction determined by the Commission to be contrary to the public interest under clause (i) may be listed or made available for clearing or trading on or through a registered entity. All they have to do is decide sports falls under (V).

jerome-yellen

Patriarch Theophilos III

SPAC_Time

[Legato Merger Corp. III Shareholders Approve Business Combination with Einride](https://www.prnewswire.com/news-releases/legato-merger-corp-iii-shareholders-approve-business-combination-with-einride-302792607.html) \- LEGT LEGT.WS It's *possible* that LEGT might be a low float play, might not. LEGT [filed an 8-K with the voting results](https://www.sec.gov/Archives/edgar/data/2002038/000182912626006114/legatomerger3_8k.htm), but no redemption numbers were released. Per the prospectus, 100% of the public shares can be redeemed, and the business combination could still close, due to the PIPE financing. The [redemption amount was around $11.08](https://www.sec.gov/Archives/edgar/data/2002038/000182912626005295/legatomerger3_defm14a.htm#:~:text=have%20amounted%20to-,approximately%20%2411.078%20per%20issued%20and%20outstanding%20Legato%20III%20Public%20Share,-.%20If%20a%20Legato), which is right where LEGT traded before the NAV floor dropped.

Midnite_07

It feels like we're gonna see World War III starting this weekend...

ryan1826

King Charles the III?

Harriers1886

So we have medical as Sch III, rec being debated on the 29th, uplisting now kicking off…. Banking surely cannot be far away!!?

Fair-Search-2324

No, but i don’t have to like it. It’s very Superman III. I feel puts after the SP seasoning might be a play, but i’m passive.

Jax_Alltrade

What about the recent rescheduling to III and the closing of the 2018 farm bill? THCa hemp was a \~$28 billion industry; if this loophole successfully closes do you believe a significant portion of that revenue will shunt towards rec/medical? If it doesn't successfully close, do you believe the media hype as the hemp industry fights back will result in further legislative changes, or at least a temporary bump in nominal value?

SangerGRBY

Keefe Thomas acquired 67,000 shares for a 5.23% stake on May 8, 2026. MBOYC Holdings LLC acquired 187,000 shares for a 14.6% stake on June 2, 2026. Merle Pearlman acquired 95,000 shares for a 7.4% stake on June 1, 2026. Carl Vernon Griffin III acquired 125,000 shares for a 9.7% stake on May 28, 2026.

cuteman

So, that's the bet on SpaceX, right? It's a casino not a sure thing inevitability. A lot of this sounds like sci-fi, but it's not that far off from the realllyyyyy impossible stuff that is 15-25 years away. You think it's 15, someone else thinks it's 5, someone else thinks its 21. Global telecom is pretty doable and easy, they're basically already doing it and ramping scale currently. Here are the next generalized milestones (roughly) Starship & Lunar Development (2026–2028) * Starship V3 Rollout: Introduction and testing of the Version 3 Starship, aiming for significantly increased payload capacity, thrust, and rapid, shortened fuel-loading phases. * Orbital Fuel Transfer: Mastering complex LEO (Low Earth Orbit) propellant depot docking and transfer, which is an absolute prerequisite for deep-space and heavy lunar missions. * Artemis III & IV: Partnering with NASA for the Artemis program, with an uncrewed Starship test and a targeted crewed lunar south pole landing. Mars Exploration Program (2026–2030s) * Uncrewed Mars Missions (2026): Launching uncrewed Starships to Mars—potentially carrying Tesla Optimus humanoid robots—to test deep-space transit and entry, descent, and landing (EDL) capabilities. * Crewed Mars Flights (Late 2020s–2029): If the 2026 autonomous test landings and LEO refueling objectives are successful, SpaceX plans to launch its first crewed interplanetary missions to Mars. * Interplanetary Fleet Scaling (2030s): Scaling to roughly 100 missions during the 2030/31 Mars transfer window, building toward a self-sustaining city over the following two decades. Space-Based Computing & Starlink (2028–Beyond) * Space Data Centers: Deploying large-scale swarms of satellites equipped with high-performance GPUs, powered by solar arrays, designed to handle orbital AI compute as early as 2028. * Direct-to-Device: Expanding the Starlink constellation to provide continuous cellular, internet, and messaging capabilities globally, bypassing traditional ground infrastructure The TAM on Global telecom alone is $2 - 2.5T so they could absorb a huge amount of that off the bat. Launches for other private companies will be large because they'll be able to do so many of them. Military/Gov love the idea of having advantages no one else has so they'll be paying dearly as welll. So by 2028 they'll be able to launch data centers at scale and I bet you'll see quite a bit going up 2026-2028. I dunno, doesn't feel that unrealistic in 5 years, we'll know how possible it is in 2-3 years but in less than 10 it could be the new reality. Have you looked at the energy production expansion in 5-10 years? It's worth a few trillion not counting increases in domestic/residential electricity and water consumption that has everyone so pissed Starship + V3 size arrays make a lot of crazy things possible. ISS required 40-50 trips to get assembled (42 just for hardware) across 13 years of projects/launches largely constrained by launches. Imagine being able to do 2-4 starship launches in 6-12 months for 1/20th the price and the hardware makes an ROI

HawaktuahMatata

Hey so I follow some space tech stuff - not a scientist by any stretch of the imagination. I’m also a retail investor, and I rock about 5% of my Roth for fun little gambles. I’ve had my eye on SpaceX for a while. Clearly Elon is close with the administration. The head of NASA is a former SpaceX test pilot. Blue Origin’s Artemis test flight just blew up. I think it’s likely SpaceX gets the Artemis III and IV contracts. Does the whole thing stink of corruption? You bet. But if someone is getting rich and going to the moon, might as well be me too…

achoo_blessyoo

Lando III

Brokenrecordcordcord

Hey there! I'm kind of a novice (but not a bot, just fyi) at buying/selling stock. I've been doing it off and on, here and there for the past few years. I bought 5000 shares of this stock. They're currently in Phase III of a new drug that helps pericarditis and it looks pretty dang promising to me. The results of that are going to be reported at some point later this year... The weekly share price floats between 1.25 and 1.35 right now, it seems, so it's just in a bit of a limbo until those results are read. But if those results are positive (and I'm hopeful that they are), this company could do very well! Just my two cents. I'm no expert, mind you! Hope that helped a little bit.

Embarrassed-Bench392

About twenty years ago I bought Information Services Group (III) for a nickel per share and sold it a short time later at $1.25 to buy a tractor. I have traded it multiple times over the years and continue to hold a position today. It pays a 4% dividend now.

Able_Web3798

Why flyin' high today? This is what I got, let me know..... 1) Today was effectively the deadline for participation/objections in the DEA Schedule III hearing process (and appears no big coordinated opposition?) ... more likely smooth sailiing than not for the June 29 DEA hearing. 2) The Curaleaf uplisting/ADR angle ..... access to more $$$, it was out 1-2 days ago, but coupled with the above, has led to it being more credible.

SPAC_Time

[Factorial and Cartesian Growth Corporation III Announce Approval of Business Combination by Cartesian Growth Shareholders](https://www.globenewswire.com/news-release/2026/05/27/3302458/0/en/factorial-and-cartesian-growth-corporation-iii-announce-approval-of-business-combination-by-cartesian-growth-shareholders.html) \- CGCT CGCTW "[Shareholders holding](https://www.sec.gov/Archives/edgar/data/2049662/000110465926067117/tm2615767d1_8k.htm#:~:text=Shareholders%20holding) 23,051,313 Class A ordinary shares exercised their right to redeem such shares for a pro rata portion of the funds in the Company’s trust account. As a result, $239,964,168.33 (approximately $10.41 per share) will be removed from the Company’s trust account to pay such shareholders. As previously reported, on December 17, 2025, the Company entered into a Stock Purchase Agreement (the “Institutional Investor Stock Purchase Agreement”) with a certain institutional investor (the “Institutional Investor”) and a Stock Purchase Agreement (the “Sponsor Investor Stock Purchase Agreement” and, together with the Institutional Investor Stock Purchase Agreement, the “Stock Purchase Agreements”) with an affiliate of CGC Sponsor III LLC, the sponsor of the Company (such affiliate, the “Sponsor Investor” and, together with the Institutional Investor, the “PIPE Investors”). Pursuant to the terms of the Stock Purchase Agreements, to the extent a PIPE Investor purchases Class A ordinary shares of the Company on the open market, and agrees (i) **not to transfer directly or indirectly such shares until the Closing** and (ii) in the case of the Institutional Investor, to vote such shares in favor of the proposals described above, or, in the case of the Sponsor Investor, to abstain from voting such shares in connection with the proposals described above, it will reduce, on a share for share basis, such PIPE Investor’s purchase obligation under its Stock Purchase Agreement. **The Institutional Investor and the Sponsor Investor elected to satisfy 2,000,000 shares and 1,470,764 shares of their respective purchase obligations through such open market purchases**." "[Class A ordinary shares subject to possible redemption](https://www.sec.gov/Archives/edgar/data/2049662/000110465926062778/tmb-20260331x10q.htm#:~:text=Contingencies%20(Note%206)-,Class%20A%20ordinary%20shares%20subject%20to%20possible%20redemption,-%2C%2027%2C600%2C000%20shares), 27,600,000 shares as of March 31, 2026 " Looks like about 1,077,923 unredeemed and tradeable shares until the closing.

stuenkes

[newcleo, A Developer of Advanced Nuclear Reactors and Nuclear Fuel, to Become Public Company Through Business Combination with NewHold Investment Corp III](https://www.globenewswire.com/news-release/2026/05/27/3301791/0/en/newcleo-a-developer-of-advanced-nuclear-reactors-and-nuclear-fuel-to-become-public-company-through-business-combination-with-newhold-investment-corp-iii.html) [ProLogium, a Next Generation Solid-State Battery Developer with 10+ Years of Proven Commercialization, to List on the Nasdaq through a Merger with Translational Development Acquisition Corp.](https://www.globenewswire.com/news-release/2026/05/27/3301774/0/en/prologium-a-next-generation-solid-state-battery-developer-with-10-years-of-proven-commercialization-to-list-on-the-nasdaq-through-a-merger-with-translational-development-acquisitio.html)

CD274

LUNR recovered because full NASA press release did in fact award them a contract: https://www.ap7am.com/en/127919/moon-base-push-marks-nasas-new-lunar-era?hl=en-US#:~:text=Moon%20Base%20III%20will%20deploy,swirls%20on%20the%20Moon's%20surface.

C130J_Darkstar

NuScale got through the NRC earlier because it’s fundamentally just a Gen III light-water reactor, not a novel Gen IV architecture. The issue was never licensing- it was economics and execution, which is why serious customer momentum largely evaporated after the CFPP collapse. The landscape is shifting now with the ADVANCE Act and DOE RPP efforts creating a far more supportive path for advanced reactors like Oklo. What makes Oklo compelling is the vertically integrated power-as-a-service model, fuel and recycling strategy, and focus on scalable fleet deployment rather than simply selling reactors. If they execute on the 2027/2028 timeline, the first-mover advantage could end up being massive.

SPAC_Time

[CPRO, a Leader in the Physical AI Security Industry, to be Publicly Listed on a U.S. National Securities Exchange Through Business Combination with Lakeshore Acquisition III Corp.](https://www.prnewswire.com/news-releases/cpro-a-leader-in-the-physical-ai-security-industry-to-be-publicly-listed-on-a-us-national-securities-exchange-through-business-combination-with-lakeshore-acquisition-iii-corp-302781369.html) \- LCCC LCCCR LCCCR = right that entitles the holder thereof to receive one-sixth (1/6) of one Ordinary Share upon consummation of the Company’s initial business combination

buttermilkmeeks

Factorial Batteries it is IPOing via Cartesian Growth III SPAC under the ticker CGCT (for a few more weeks) and will become FAC

drytexterfinalboss

Self defense strike here and self defense strike there Before you know we get a self defense world war III LMAO 🤌

dljmonkeyboiz

Al bin sulamin III said they just got there though

MatrixOrigin

>“We fundamentally disagree with the court’s decision today. All parties demonstrated substantial injury that exceeds the threshold required by Article III,” SAM President and CEO Kevin Sabet said. GTFO 🤡

Total_Schedule591

Arthritis III

Silver_Variety_1108

I was a young investor back then and made more than my share of mistakes. Now, I try to get into new growing sectors. I got into 2 drone stocks in 2024 and they have 6x. Now, today I think $DRTS a small, unknown Biotech that has found a better way to treat solid cancer tumors. They already have been approved for Head &Neck cancer in Japan. They have shown very little side effects because their targeted therapy kills the cancer, but not the surrounding healthy tissue. In brain cancer, they showed 100% control at 67% complete responses. In skin cancer, it’s nearly 100% effective. They are starting with Pancreatic cancer. The best part is, their treatments do not impair the immune system like chemotherapy and full body radiation does. I also like $SLS! They have 2 drugs for AML. Their phase III regal trial has gone on much longer than expected. That is a great sign because it shows patients are living longer.

King_Chron

Don't buy into the media panic on this one. TerrAscend didn't just mess up their taxes, this is actually a calculated move in a massive game of chicken between the weed industry and the feds. The cash flow strategy here is wild. Since cannabis companies can't get normal bank loans, they usually have to go to predatory lenders who charge crazy interest rates like 15 percent or more. Instead, these companies realized they could file amended tax returns, get an automatic refund check from the IRS, and immediately cash it. Even if the IRS comes back years later demanding the money back with standard interest, that federal underpayment rate is only around 7 percent. The MSOs basically figured out how to use the IRS as a cheap bridge loan to keep scaling their businesses. TerrAscend's 8.3 million is nothing compared to the bigger picture. Publicly traded operators are sitting on something like 1.6 billion dollars in contested 280E taxes right now. Trulieve has nearly 450 million on the line, Verano has almost 380 million, and Cresco is around 170 million. The IRS is sweating because if they don't fight TerrAscend immediately, every major operator is going to walk away from their old tax bills. The top law firms representing these companies actually want this fight. They are using these refund demands to drag the IRS into court, hoping a federal judge will finally rule that 280E is an unconstitutional burden on state legal businesses. Now that the feds are moving cannabis to Schedule III, 280E is going away for future taxes anyway, so the whole war right now is over the past. The industry is basically arguing that because the government now admits cannabis has medical value, they never should have been paying those insane tax rates in the first place. TLDR: The big weed companies triggered these lawsuits on purpose to force a definitive court ruling. They are betting that federal judges or the new Schedule III rules will wipe out their old tax debts before the IRS can actually force them to pay.

JellyfishFestival

One of the many problems with the SpaceX IPO is how the company has to develop most of the technologies and processes to be fantastically profitable. They don't currently exist, or exist at any commercially profitable scale. Doing that requires time, innovating things that don't exist, waiting on pre-requisite technologies, and most importantly for investors...massive amounts of capex and dilution to fund that capex. It's like valuing Nvidia as a $2T company back in 1999 when it was making graphics chips for Pentium III towers but a sci-fi mag talked about the idea of super intelligent robots.

Magikarp_to_Gyarados

>He pays other people to come up with ideas, buys them or steals them, then takes credit.  That's more or less the same as Steve Jobs. Before Apple, Steve Jobs worked at Atari. Atari co-founder Nolan Bushnell challenged Jobs to create a video game called "Breakout" using a small number of chips. Bushnell offered Jobs something like $750 for the project, and a $5000 bonus for designing the game with a small number of chips. Jobs convinced Wozniak to design the game, giving him half of the $750 fee. However, Jobs kept the $5000 bonus for himself and never told Wozniak of its existence. Wozniak only found out about the deception many years later. >He isn't a visionary and most of his actual ideas like Optimus and Cybertruck are half baked, shitty and poorly executed. The same could be said of many Apple products during Jobs' first tenure. Apple III was a dud. Same with the Lisa workstation. Many of the early Macintosh machines were underspec'd. The talking Mac demo was a customized machine that wasn't representative of the actual consumer product. The original MacOS itself was a crufty mess that hampered Apple until the entire codebase was thrown out for OS X in the early 2000s.

Hot_Set597

Tomorrow is **El Día del Toro** in Spain — a centuries-old tradition where the entire country honors the bull. Dating back to 1387, Spanish law mandates that any stock with "bull" in the name must open 10% higher on this sacred day. Charles III wrote it into law in 1764 after a bull saved his favorite horse from a wolf. The horse's name was Webull. $BULL. You've been warned.

WinstonSalemSmith

Superman III, Richard Pryor

RJ5R

Who stands to profit? The suppliers, distributors, retail, all 3? How can we get in on this trade? [https://www.reddit.com/r/oil/comments/1tfvbqp/motor\_oil\_is\_the\_next\_shortage\_and\_its\_just\_as/?sort=new](https://www.reddit.com/r/oil/comments/1tfvbqp/motor_oil_is_the_next_shortage_and_its_just_as/?sort=new) The summary: Shell's plant in Qatar was hit by Iran taking it offline for what could be 2 years. They refine the base formulation for both MOBIL1 and Pennzoil. Other plants hit as well. In total, around \~55% of the US Group III base oils come from gulf region and the current output is 0. Toyota, Nissan, Autozone, and others began to sound the alarm as early as mid April. We are now 1 month after that initial alarm and the shortages of 0W-16 and 0W-8 are imminent. You can do some "diluting" to stretch supply using 0W-20 as a temporary measure, so they're saying that eventually this could also cause 0W-20 prices to spike as well. O'Reilly's has already stopped bulk purchases of 0W-16 and 0W-8. If you drive any vehicles that use these grades of oil, I highly suggest you go and buy enough to get you through the rest of the year maybe even through next year. The Walmart near me only had 4 jugs left of 0W-16

RJ5R

Who stands to profit? The suppliers, distributors, retail, all 3? How can we get in on this trade? [https://www.reddit.com/r/oil/comments/1tfvbqp/motor\_oil\_is\_the\_next\_shortage\_and\_its\_just\_as/?sort=new](https://www.reddit.com/r/oil/comments/1tfvbqp/motor_oil_is_the_next_shortage_and_its_just_as/?sort=new) The summary: Shell's plant in Qatar was hit by Iran taking it offline for what could be 2 years. They refine the base formulation for both MOBIL1 and Pennzoil. Other plants hit as well. In total, around \~55% of the US Group III base oils come from gulf region and the current output is 0. Toyota, Nissan, Autozone, and others began to sound the alarm as early as mid April. We are now 1 month after that initial alarm and the shortages of 0W-16 and 0W-8 are imminent.

type_error

How about Ebola III?

Jerikolol

there's another bullish upside for RELX/WKL? theres the **EU AI Act** thats being discussed in september afaik. Its important because in Annex III of the Act, AI systems utilized in the "Administration of Justice and Democratic Processes" are explicitly classified as High-Risk. This would ad a bunch of new rules and oversight + obligatory human in the loop obligations, which could make it too much of a hassle for claude for example to want to comply with, or ad so much extra friction, that it could be 'regulated out'. Which obviously would be quite bullish for RELX/WKL, who dont have these issues. TBD how this develops.

justinwfreed

Here's a couple that fit into the "advanced materials" sector but also fit into today's push into photonics. ALMU - currently transitioning from R&D to commercialization, their quantum dot photo detectors utilize III-V semiconductor materials made of Indium and gallium arsenide grown on a Si substrate. LWLG - These people have a proprietary polymer that achieves extremely high electro-optic (EO) coefficients that can "modulate" light (sort of like modulating RF) at very high speeds with very low energy consumption. Not quite as far along commercialization-wise as ALMU but certainly worth checking out.

Visual-Try-8081

Isn't GTBIF profitable? Or HITI? I don't buy the “not profitable” argument. GTBIF has a $300 million cash war chest and very little debt. How did they achieve that if they’re not profitable? There are companies in the market that lose money or generate only a small fraction of that revenue, yet still have insane valuations. GTBIF is trading at only a 1.3x valuation. This isn’t about profitability. This is about OTC, MSOS ETF, short selling, options, and manipulation. I’ll patiently wait for Schedule III and uplisting. After that, we’ll see how it works out. For now, I’m just holding the stocks and obviously not buying options.

Silver_Variety_1108

I think some selective Bio Tech stocks will outperform. Specifically $SLS for 2 AML drugs (GPS and SLS009). As they have shown to keep patients alive much longer vs current standard of care. Regal Phase III is nearing its completion and all the research is showing a very high probability of success. Also $DRTS is showing great results in reducing Solid tumor cancers. They are in 5 trials, all showing great effectiveness in shrinking tumors and in some cases eliminating cancer completely. They inject radiation directly into the cancer tumor. This way, the cancer is killed, but the surrounding healthy tissue remains intact. This way, fewer side effects vs chemotherapy and full body radiation. They are already approved for Head and Neck cancer in Japan. They are farthest along in skin cancer. They report on Pancreatic cancer in about a week.

Impossible_Use_9194

Hyperscale Data, Inc. (GPUS) has experienced an incredibly busy week, marked by major corporate announcements, a massive stock surge, and critical updates regarding its AI data center operations. ​1. The Big News: $5 Million Premium Tender Offer ​The company announced its intent to launch a cash tender offer to repurchase up to $5,000,000 of its Class A Common Stock at $0.21 per share. ​The Premium: This offer price sits well above its recent trading range (~$0.12–$0.14). ​The Reason: Executive Chairman Todd Ault III stated there is a "material disconnect" between the market price and the company's actual asset value. Management reports that its net book value per share is $0.26 based on holding nearly $94 million to $100 million in combined cash, restricted cash, and Bitcoin. ​Timing: The buyback will formally launch once the company files its Q1 10-Q report. ​2. Preliminary Q1 Earnings & Delay ​Alongside the buyback news, Hyperscale Data filed a Form 12b-25 to delay its official Q1 2026 earnings report, but it provided a preliminary snapshot of its financials: ​Revenue: Up roughly 76% year-over-year to $44 million. ​Net Loss: Tracking at approximately $30 million, primarily driven by a $12 million charge related to fluctuations in digital asset prices. ​3. Expansion Into Intelligent Robotics ​Its subsidiary, Omnipresent Robotics, signed a major deal with AGIBOT to acquire up to 143 intelligent robots. Hyperscale Data has allocated a 100,000-square-foot portion of its Michigan Data Center to serve as a U.S. hub for robotics data collection, teleoperation bays, and AI training models. ​4. Progress on Michigan 300 MW AI Compute Campus ​The company reported heavy customer interest in leasing AI compute infrastructure at its Michigan facility. It has already paid for the initial equipment to support its first 30 MW buildout and is evaluating long-term expansion plans to scale the campus past 300 MW of total capacity. ​5. Bitcoin Treasury Update ​The company confirmed its current digital asset holdings stand at 686.72 Bitcoin, which are securely held via its subsidiaries Sentinum and Ault Capital Group. ​What to Watch Next ​Management is expected to hold a conference call on or around May 20, 2026, to officially release its full Q1 results and lay out its upcoming capital market and treasury initiatives.

RD_006

Think of how stupid the average person is, and realize half of them are stupider than that. (C) George Warren Carlin Buffet III The Esquire

Impossible_Use_9194

(GPUS) has experienced an incredibly busy week, marked by major corporate announcements, a massive stock surge, and critical updates regarding its AI data center operations. 1. The Big News: $5 Million Premium Tender Offer The company announced its intent to launch a cash tender offer to repurchase up to $5,000,000 of its Class A Common Stock at $0.21 per share. The Premium: This offer price sits well above its recent trading range (~$0.12–$0.14). The Reason: Executive Chairman Todd Ault III stated there is a "material disconnect" between the market price and the company's actual asset value. Management reports that its net book value per share is $0.26 based on holding nearly $94 million to $100 million in combined cash, restricted cash, and Bitcoin. Timing: The buyback will formally launch once the company files its Q1 10-Q report. 2. Preliminary Q1 Earnings & Delay Alongside the buyback news, Hyperscale Data filed a Form 12b-25 to delay its official Q1 2026 earnings report, but it provided a preliminary snapshot of its financials: Revenue: Up roughly 76% year-over-year to $44 million. Net Loss: Tracking at approximately $30 million, primarily driven by a $12 million charge related to fluctuations in digital asset prices. 3. Expansion Into Intelligent Robotics Its subsidiary, Omnipresent Robotics, signed a major deal with AGIBOT to acquire up to 143 intelligent robots. Hyperscale Data has allocated a 100,000-square-foot portion of its Michigan Data Center to serve as a U.S. hub for robotics data collection, teleoperation bays, and AI training models. 4. Progress on Michigan 300 MW AI Compute Campus The company reported heavy customer interest in leasing AI compute infrastructure at its Michigan facility. It has already paid for the initial equipment to support its first 30 MW buildout and is evaluating long-term expansion plans to scale the campus past 300 MW of total capacity. 5. Bitcoin Treasury Update The company confirmed its current digital asset holdings stand at 686.72 Bitcoin, which are securely held via its subsidiaries Sentinum and Ault Capital Group. What to Watch Next Management is expected to hold a conference call on or around May 20, 2026, to officially release its full Q1 results and lay out its upcoming capital market and treasury initiatives.

Impossible_Use_9194

Hyperscale Data, Inc. (GPUS) has experienced an incredibly busy week, marked by major corporate announcements, a massive stock surge, and critical updates regarding its AI data center operations. ​1. The Big News: $5 Million Premium Tender Offer ​The company announced its intent to launch a cash tender offer to repurchase up to $5,000,000 of its Class A Common Stock at $0.21 per share. ​The Premium: This offer price sits well above its recent trading range (~$0.12–$0.14). ​The Reason: Executive Chairman Todd Ault III stated there is a "material disconnect" between the market price and the company's actual asset value. Management reports that its net book value per share is $0.26 based on holding nearly $94 million to $100 million in combined cash, restricted cash, and Bitcoin. ​Timing: The buyback will formally launch once the company files its Q1 10-Q report. ​2. Preliminary Q1 Earnings & Delay ​Alongside the buyback news, Hyperscale Data filed a Form 12b-25 to delay its official Q1 2026 earnings report, but it provided a preliminary snapshot of its financials: ​Revenue: Up roughly 76% year-over-year to $44 million. ​Net Loss: Tracking at approximately $30 million, primarily driven by a $12 million charge related to fluctuations in digital asset prices. ​3. Expansion Into Intelligent Robotics ​Its subsidiary, Omnipresent Robotics, signed a major deal with AGIBOT to acquire up to 143 intelligent robots. Hyperscale Data has allocated a 100,000-square-foot portion of its Michigan Data Center to serve as a U.S. hub for robotics data collection, teleoperation bays, and AI training models. ​4. Progress on Michigan 300 MW AI Compute Campus ​The company reported heavy customer interest in leasing AI compute infrastructure at its Michigan facility. It has already paid for the initial equipment to support its first 30 MW buildout and is evaluating long-term expansion plans to scale the campus past 300 MW of total capacity. ​5. Bitcoin Treasury Update ​The company confirmed its current digital asset holdings stand at 686.72 Bitcoin, which are securely held via its subsidiaries Sentinum and Ault Capital Group. ​What to Watch Next ​Management is expected to hold a conference call on or around May 20, 2026, to officially release its full Q1 results and lay out its upcoming capital market and treasury initiatives.

Impossible_Use_9194

Hyperscale Data, Inc. (GPUS) has experienced an incredibly busy week, marked by major corporate announcements, a massive stock surge, and critical updates regarding its AI data center operations. ​1. The Big News: $5 Million Premium Tender Offer ​The company announced its intent to launch a cash tender offer to repurchase up to $5,000,000 of its Class A Common Stock at $0.21 per share. ​The Premium: This offer price sits well above its recent trading range (~$0.12–$0.14). ​The Reason: Executive Chairman Todd Ault III stated there is a "material disconnect" between the market price and the company's actual asset value. Management reports that its net book value per share is $0.26 based on holding nearly $94 million to $100 million in combined cash, restricted cash, and Bitcoin. ​Timing: The buyback will formally launch once the company files its Q1 10-Q report. ​2. Preliminary Q1 Earnings & Delay ​Alongside the buyback news, Hyperscale Data filed a Form 12b-25 to delay its official Q1 2026 earnings report, but it provided a preliminary snapshot of its financials: ​Revenue: Up roughly 76% year-over-year to $44 million. ​Net Loss: Tracking at approximately $30 million, primarily driven by a $12 million charge related to fluctuations in digital asset prices. ​3. Expansion Into Intelligent Robotics ​Its subsidiary, Omnipresent Robotics, signed a major deal with AGIBOT to acquire up to 143 intelligent robots. Hyperscale Data has allocated a 100,000-square-foot portion of its Michigan Data Center to serve as a U.S. hub for robotics data collection, teleoperation bays, and AI training models. ​4. Progress on Michigan 300 MW AI Compute Campus ​The company reported heavy customer interest in leasing AI compute infrastructure at its Michigan facility. It has already paid for the initial equipment to support its first 30 MW buildout and is evaluating long-term expansion plans to scale the campus past 300 MW of total capacity. ​5. Bitcoin Treasury Update ​The company confirmed its current digital asset holdings stand at 686.72 Bitcoin, which are securely held via its subsidiaries Sentinum and Ault Capital Group. ​What to Watch Next ​Management is expected to hold a conference call on or around May 20, 2026, to officially release its full Q1 results and lay out its upcoming capital market and treasury initiatives.

SPAC_Time

[Cantor Equity Partners III Shareholders Approve Business Combination with AIR](https://www.reddit.com/r/Spacstocks/comments/1tcw9se/cantor_equity_partners_iii_shareholders_approve/) \- CAEP Shareholders approved on May 12. "In light of receipt of the requisite approvals by CAEP Shareholders described above, CAEP expects the Business Combination to be completed promptly following the satisfaction or waiver of the other conditions to the consummation of the Business Combination."

LittlePlacerMine

The rescheduling for medical has already occurred. DEA is holding hearings on non-medical next month and there is a bill in the house that would grant adult use non medical schedule III status. (Not a given some of the house are anti cannabis) But the schedule III for medical is a big win for the big 3 cannabis companies, their tax relief is hundreds of millions. I think the big institutions are holding back waiting for a safe harbor ruling/memo. Otherwise the big banks can’t hold their shares for them.

InfinitelyFinite212

TLDR: * Cannabis was partially moved to Schedule III * This mainly applies to FDA-approved cannabis drugs and state medical cannabis businesses * Recreational/adult-use cannabis is still Schedule I * Medical operators may get 280E tax relief starting in 2026 * Medical operators must register with the DEA * This does not federally legalize cannabis * This does not fix banking or pass SAFE Banking * DOJ is still reviewing whether all cannabis, including adult-use, should move to Schedule III * Legal challenges are likely

PhysicalConsistency

The hell are you talking about? It's been pumping for a decade. The DJIA was 17,540 on May 9, 2016. It's hovering around 50k today. That has nothing to do with China's oil supply or Hormuz or AI or anything else. Even if the AI bubble popped tomorrow, even if WTI spiked to $150/barrel, even if a comet was on a direct course for earth, it will continue to pump until world war III destabilizes the governments which are enabling this inflation stashing. We learned the worst lesson from the great recession, and that lesson was that shit doesn't have to go down if we don't want it to.

BeebleBoxn

Something, something, something, something. No apocalypse, No world War III, No giant asteroid, yeah same old shit in one big loop.

BrightViolinist2362

$DNMXW Dynamix III warrants with some volume today, its been trading weirdly last couple of weeks, big bidder keeps showing up with 30-50k on bid then disappears.

vakr001

Options ARE hard… 1) Most retail investors shouldn’t touch them. Only in the past 10 - 15 years have they become more popular. 2) You need to have a strategy in place, do your homework, and be void of ALL emotion. This is extremely hard. 3) *One minute you're up half a million in soybeans and the next, boom, your kids don't go to college and they've repossessed your Bentley.* Louis Winthorpe III. This quote is so true for Options.

AVBforPrez

That's JP Morgan Chase III, didn't you realize?

KingoftheWildlings

I just need a little World War III action with a hint of bubonic plague, and a new chair of federal reserve who HATES growth and my puts will print

Opening_Normal

Or people realized that Schedule III won't actually help the MSOS much...

CumomEileen

I still don’t get it tbh, what difference does it make to MMs if a stock is trading at $400 or $80 with the same market cap? Garcia III said it was about making the stock more affordable for employees which sounds like total BS so I want to understand what his agenda really is

Thumbszilla

They had a revenue miss (approximately 6.2%) but had positive forward-looking guidance regarding Schedule III reclassification, which is expected to drastically improve future earnings by eliminating the 280E tax burden. Bullish!